Show simple item record

dc.contributor.authorLim, SL
dc.contributor.authorSmith, P
dc.contributor.authorSyed, N
dc.contributor.authorCoens, C
dc.contributor.authorWong, H
dc.contributor.authorvan der Burg, M
dc.contributor.authorSzlosarek, P
dc.contributor.authorCrook, T
dc.contributor.authorGreen, JA
dc.date.accessioned2018-08-30T13:39:31Z
dc.date.issued2008-04-22
dc.identifier8
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2008, 98 pp. 1452 - 1456
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2426
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/sj.bjc.6604325
dc.description.abstractThe Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy. This study sought to confirm this hypothesis in cell lines and a large series of ovarian cancer samples. Promoter methylation was assessed by methylation-sensitive polymerase chain reaction of FANCF in nine ovarian cancer cell lines and 74 ovarian cancer samples taken from patients entered on a trial of cisplatin-based chemotherapy. This study confirmed methylation-dependent silencing of FANCF in one out of nine ovarian cancer cell lines. Methylation of FANCF was demonstrated in 13.2% of 53 evaluable ovarian tumour samples. Progression-free survival gave an HR of 3.63 ( 95% CI: 1.54 - 8.54, P = 0.0016) in favour of the unmethylated cases. There was no association with overall survival. This study does not support methylation-dependent silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer.
dc.format.extent1452 - 1456
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.titlePromoter hypermethylation of FANCF and outcome in advanced ovarian cancer
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6604325
rioxxterms.licenseref.startdate2008-04-22
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF CANCER
pubs.notesaffiliation: Green, JA (Reprint Author), Univ Liverpool, Sch Canc Studies, Div Surg & Oncol, Liverpool L7 8XP, Merseyside, England. Lim, S. L.; Green, J. A., Univ Liverpool, Sch Canc Studies, Div Surg & Oncol, Liverpool L7 8XP, Merseyside, England. Lim, S. L.; Smith, P.; Syed, N.; Crook, T., Breakthrough Toby Robins Breast Canc Res Ctr, Inst Canc Res, Chester Beatty Labs, London, England. Coens, C., EORTC Data Ctr, Brussels, Belgium. Wong, H., Clatterbridge Ctr Oncol NHS Trust, Wirral, Merseyside, England. van der Burg, M., Erasmus Univ, Med Ctr, Rotterdam, Netherlands. Szlosarek, P., Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Lung & Mesothelioma Unit, London, England. keywords: ovarian cancer; Fanconi genes; platinum resistance; clinical trial keywords-plus: ANEMIA-BRCA PATHWAY; CISPLATIN; SURVIVAL; METHYLATION; CELL; DISRUPTION; TUMORS; DNA research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] number-of-cited-references: 17 times-cited: 34 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Br. J. Cancer doc-delivery-number: 288SU unique-id: ISI:000255006900021 oa: gold_or_bronze da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume98
pubs.embargo.termsNot known
dc.contributor.icrauthorCrook, Timothyen
dc.contributor.icrauthorSyed, Neloferen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record